Global pancreatic cancer therapy market, based on the type was segmented into endocrine pancreatic cancer and exocrine pancreatic cancer. In 2017, the exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this cancer is majorly occurring cancer type among the two and thus is expected to have massive patient pool over the forecast years.
Pancreatic cancer begins when the cells in the pancreas grow uncontrollably. Based on the type of cell affected, pancreatic cancer can be classified into two types, exocrine tumors, and endocrine tumors. These tumors behave differently. Hence they are treated differently. Pancreatic cancer generally diagnosed at a later stage since the symptoms are not easily detected or diagnosed. Factors such as chronic inflammation of the pancreas (pancreatitis), diabetes, smoking, and obesity are some of the identified causes of pancreatic cancer. The pancreatic cancer therapy market growth is attributed to factors such as rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs and increase in number of therapies launched in the market. Additionally, development of efficient therapy for pancreatic cancer treatment is expected to stimulate the market during the forecast period. However, side effects of the therapies and low success rate of treatments are expected to restrain the market of pancreatic cancer therapy.
Request For Exclusive Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPMD00002009/
According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of death related to cancer in the US and is expected to be the second leading cause of death by 2020. According to Cancer Research UK, approximately 9,921 new cases of pancreatic cancer were diagnosed in the UK in 2015, while 8,912 patients died due to same cancer.
For instance, the American Cancer Society suggests that pancreatic cancer accounts for approximately 3% of deaths of all cancers in the US. According to the National Institute of Health, an estimated of 68,615 patients in 2015 were living with pancreatic cancer in the US.
The major players operating in the pancreatic cancer therapy market include Eli Lilly and Company, F. Hoffmann-La Roche AG, Celgene Corporation, Amgen Inc., Novartis AG, Pharmacyte Biotech Inc., Clovis Oncology, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc. among others. For instance, in May 2018, Eli Lilly and Company acquired AMRO BioSciences. AMRO BioSciences is engaged into number of drugs for cancer. The clinical trial explores a drug (pegilodecakin) which is ongoing for the pancreatic cancer. The drug is into phase III of the clinical trials. The developments performed by the companies are helping the market to grow in the coming years.
The market for pancreatic cancer therapy is expected to grow due to rise in number of patients suffering with pancreatic cancer, increasing healthcare expenditures for pancreatic drugs, and increase in number of therapies launched in the market are boosting the market over the years. In addition, development of efficient therapy for pancreatic cancer treatment are likely to have a positive impact on the growth of the pancreatic cancer therapy market in the coming years.
TABLE OF CONTENTS
1. INTRODUCTION 18
1.1 SCOPE OF THE STUDY 18
1.2 THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE 18
2. GLOBAL PANCREATIC CANCER THERAPY MARKET – KEY TAKEAWAYS 19
3. GLOBAL PANCREATIC CANCER THERAPY MARKET – MARKET LANDSCAPE 21
3.1 OVERVIEW 21
3.2 MARKET SEGMENTATION 21
3.3 GLOBAL PANCREATIC CANCER THERAPY MARKET – BY TYPE 22
3.4 GLOBAL PANCREATIC CANCER THERAPY MARKET – BY THERAPY 22
3.5 GLOBAL PANCREATIC CANCER THERAPY MARKET – BY GEOGRAPHY 23
3.6 PEST ANALYSIS 24
3.6.1 North America – PEST Analysis 24
3.6.2 Europe- PEST Analysis 26
3.6.3 Asia Pacific- PEST Analysis 28
3.6.4 Middle East And Africa- PEST Analysis 30
3.6.5 South and Central America – PEST Analysis 32
4. GLOBAL PANCREATIC CANCER THERAPY MARKET – KEY MARKET DYNAMICS 34
4.1 KEY MARKET DRIVERS 34
4.1.1 Rise in Number of Patients Suffering with Pancreatic Cancer 34
4.1.2 Increasing Healthcare Expenditures for Pancreatic Drugs 34
4.1.3 Increase in Number of Therapies Launched in the Market 35
4.2 KEY MARKET RESTRAINTS 35
4.2.1 Side Effects of the Therapies 35
4.2.2 Low Success Rate of Treatments 35
4.3 KEY MARKET OPPORTUNITIES 36
4.3.1 Development of Efficient Therapy for Pancreatic Cancer Treatment 36
4.4 FUTURE TRENDS 36
4.4.1 Rapid Adoption of Combination Therapy Over Monotherapy 36
4.5 IMPACT ANALYSIS 37
5. PANCREATIC CANCER THERAPY MARKET – GLOBAL ANALYSIS 38
5.1 GLOBAL PANCREATIC CANCER THERAPY MARKET REVENUE FORECASTS AND ANALYSIS 38
5.2 GLOBAL PANCREATIC CANCER THERAPY MARKET, BY GEOGRAPHY – FORECASTS AND ANALYSIS 39
5.3 EXPERT OPINIONS 40
6. PANCREATIC CANCER THERAPY MARKET ANALYSIS- BY TYPE 41
6.1 OVERVIEW 41
6.1.1 Endocrine Pancreatic Cancer 42
6.1.2 Overview 42
6.1.3 Global Endocrine Pancreatic Cancer Therapy Market Revenue and Forecasts to 2025 (US$ Mn) 42
6.1.4 Exocrine Pancreatic Cancer 43
220.127.116.11 Overview 43
18.104.22.168 Global Exocrine Pancreatic Cancer Therapy market Revenue and Forecasts to 2025 (US$ Mn) 43
Interested in Purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPMD00002009/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email